Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00264446 · ClinicalTrials.gov registry record · Phase 1
A Study of ADH300004 in Surgically Resected Primary or Metastatic Colorectal Cancer and Liver Biopsy, or Planned Hepatic Resection
A Phase 1 study, sponsored by Adherex Technologies.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00264446 is a Phase 1 study that has completed, run by Adherex Technologies.
The verdict
NCT00264446, a Phase 1 study, has completed, sponsored by Adherex Technologies.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
5 fluorouracil (5 FU), one of the most actively investigated anti-cancer drugs, is rapidly inactivated by the enzyme dihydropyrimidine dehydrogenase (DPD). ADH300004 blocks DPD. This study will examine the kinetics of inhibition and recovery of the metabolic pathways for fluoropyrimidines in subjects who receive a single oral dose of ADH300004, and may allow optimization of oral 5 FU dosing to subjects in future studies.
Interventions
- DRUG ADH300004
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00264446
The ClinicalTrials.gov registry entry for NCT00264446 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Adherex Technologies, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ADH300004 is the first listed.
NCT00264446 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00264446 about?
NCT00264446 is a clinical study titled "A Study of ADH300004 in Surgically Resected Primary or Metastatic Colorectal Cancer and Liver Biopsy, or Planned Hepatic Resection". 5 fluorouracil (5 FU), one of the most actively investigated anti-cancer drugs, is rapidly inactivated by the enzyme dihydropyrimidine dehydrogenase (DPD). ADH300004 blocks DPD. This study will examine the kinetics of inhibition and recovery of the metabolic pathways for fluoropyrimidines in subject...
What is the current status of trial NCT00264446?
This trial is currently completed. It is a Phase 1 study.
What interventions are being tested in trial NCT00264446?
The interventions under investigation include: ADH300004 (DRUG).
Who is sponsoring clinical trial NCT00264446?
This trial is sponsored by Adherex Technologies, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.